$29m market cap
$1.25 last close
OpGen is focused on revolutionizing the identification and treatment of bacterial infections. Following the merger with Curetis, it has technology platforms to detect pathogens and predict resistance. Importantly, the AMR Gene Panel and Unyvero platforms have the ability to provide results in hours instead of days.
Investment summary
OpGen is a diagnostic company focused on revolutionising the identification and treatment of bacterial infections. It recently merged with Curetis, a Germany-based molecular diagnostics company with a complimentary focus on infectious disease. Curetis has two main business lines: the Unyvero A50 high-plex polymerase chain reaction platform for the diagnosis of infectious disease in hospital patients, and the ARES AMR database (ARESdb), which includes data on 40,000 sequenced strains with a focus on resistant pathogens.
Y/E Dec |
Revenue (US$m) |
EBITDA (US$m) |
PBT (US$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2018A | 2.9 | (13.2) | (13.4) | (4445.0) | N/A | N/A |
| 2019A | 3.5 | (11.7) | (11.9) | (738.0) | N/A | N/A |
| 2020E | 7.1 | (21.4) | (21.6) | (139.0) | N/A | N/A |
| 2021E | 12.5 | (17.9) | (18.1) | (116.0) | N/A | N/A |
Industry outlook
It currently takes days to test a patient sample to find out if they have an infection, what they are infected with and to which drugs that infection might be susceptible. This can lead to a delay in treatment or the wrong treatment being prescribed. According to the Centers for Disease Control and Prevention, there are over two million cases of drug-resistant bacterial infections every year.
Last updated on 03/12/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (US$m) | 28.7 |
| Forecast gearing ratio (%) | 204 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Evan Jones | CEO |
| Tim Dec | CFO |
You may also be interested in…
- Abacus Health Products
- Atossa Genetics
- Auris Medical Holding
- Australis Capital
- Bioasis Technologies
- BioLargo
- CASI Pharmaceuticals
- Cellular Biomedicine Group
- Hepion Pharmaceuticals
- InMed Pharmaceuticals
- International Stem Cell
- Jaguar Health
- Orexigen Therapeutics
- PDL BioPharma
- Sunesis Pharmaceuticals
- VolitionRx